Generating Various Molecular Representations for Chemicals,
Proteins, DNAs, RNAs and Their Interactions
Calculating 293 chemical descriptors and 14 kinds of chemical fingerprints, 9920 protein descriptors based on protein sequences, more than 6000 DNA/RNA descriptors from nucleotide sequences, and six types of interaction descriptors using three different combining strategies.
Min-feng Zhu <wind2zhu@163.com>, Jie Dong <biomed@csu.edu.cn>,
Dong-sheng Cao <oriental-cds@163.com>
RCurl, rjson, rcdk (>= 3.3.2), Biostrings, GOSemSim,
ChemmineR, fmcsR, pls, randomForest, utils, stats, graphics,
methods, org.Hs.eg.db
Software, DataImport, DataRepresentation, FeatureExtraction,
Cheminformatics, BiomedicalInformatics, Proteomics, GO,
GraphAndNetwork, SystemsBiology

RCurl, rjson, rcdk (>= 3.3.2), Biostrings, GOSemSim, MASS,
ChemmineR, fmcsR, pls, randomForest, utils, stats, graphics,
methods, org.Hs.eg.db

c(person("Jeremy", "Roth", email = "jhroth@uw.edu", role = c("aut", "cre")),
person("Kathleen", "F. Kerr", email = "katiek@uw.edu", role = c("aut")),
person("Kathlee", "Zhu", email = "zhukehao@uw.edu", role = c("aut")))
Prognostic Enrichment is a clinical trial strategy of evaluating an intervention in a patient population with a higher rate of the unwanted event than the broader patient population (R. Temple (2010) <DOI:10.1038/clpt.2010.233>). This higher event rate translates to a lower sample size for the clinical trial, which can have both practical and ethical advantages. This package is a tool to help evaluate biomarkers for prognostic enrichment of clinical trials.
Jeremy Roth [aut, cre],
Kathleen F. Kerr [aut],
Kathlee Zhu [aut]

c(person("Jeremy", "Roth", email = "jhroth@uw.edu", role=c("cre", "aut")),
person("Kathleen", "F. Kerr", email = "katiek@uw.edu", role="aut"),
person("Kehao", "Zhu", email = "zhukehao@uw.edu", role="aut"))
Prognostic Enrichment is a clinical trial strategy of evaluating an intervention in a patient population with a higher rate of the unwanted event than the broader patient population (R. Temple (2010) <DOI:10.1038/clpt.2010.233>). A higher event rate translates to a lower sample size for the clinical trial, which can have both practical and ethical advantages. This package is a tool to help evaluate biomarkers for prognostic enrichment of clinical trials.
Jeremy Roth [cre, aut],
Kathleen F. Kerr [aut],
Kehao Zhu [aut]